Michael W Coleman

8088340, Jan 3, 2012

Mar 14, 2006

11/908170

Mitsutaka Matsumoto - Tokyo, JP
Sumio Shibahara - Tokyo, JP
Takayuki Matsumoto - Tokyo, JP
Kanehisa Yokoyama - Tokyo, JP
Sohei Funaoka - Tokyo, JP
Daisuke Masuda - Tokyo, JP
Michael Patrick Coleman - Louisville CO, US
Dominic Zichi - Boulder CO, US

Sumitomo Bakelite Company, Ltd. - Tokyo
Somalogic, Inc. - Boulder CO

G01N 33/52

422420, 422425, 525 541, 4352872, 4352877, 4352878

A biochip substrate capable of realizing the high detection accuracy by restricting a nonspecific adsorption or bonding of a substance to be detected, when used for a detection or analysis of protein, nucleic acids and the like. The biochip substrate is for fixing a biologically active substance on a surface of a solid substrate, and characterized in that it has a layer comprising a polymer compound obtained by copolymerizing an ethylenically unsaturated polymerizable monomer having an alkylene glycol residue, an ethylenically unsaturated polymerizable monomer having a functional group for fixing a biologically active substance and an ethylenically unsaturated polymerizable monomer having a cross-linkable functional group, on the surface of the substrate.

8293190, Oct 23, 2012

Nov 29, 2011

13/306240

Mitsutaka Matsumoto - Tokyo, JP
Sumio Shibahara - Tokyo, JP
Takayuki Matsumoto - Tokyo, JP
Kanehisa Yokoyama - Tokyo, JP
Sohei Funaoka - Tokyo, JP
Daisuke Masuda - Tokyo, JP
Michael Patrick Coleman - Louisville CO, US
Dominic Zichi - Boulder CO, US

Sumitomo Bakelite Company, Ltd. - Tokyo
Somalogic, Inc. - Boulder CO

G01N 33/52

422420, 422425, 525 541, 4352872, 4352877, 4352878

A biochip substrate capable of realizing the high detection accuracy by restricting a nonspecific adsorption or bonding of a substance to be detected, when used for a detection or analysis of protein, nucleic acids and the like. The biochip substrate is for fixing a biologically active substance on a surface of a solid substrate, and characterized in that it has a layer comprising a polymer compound obtained by copolymerizing an ethylenically unsaturated polymerizable monomer having an alkylene glycol residue, an ethylenically unsaturated polymerizable monomer having a functional group for fixing a biologically active substance and an ethylenically unsaturated polymerizable monomer having a cross-linkable functional group, on the surface of the substrate.

8605149, Dec 10, 2013

Jul 19, 2011

13/186004

Robert S. Conrad - Wheaton IL, US
Paul L. Falkenstein - West Chester PA, US
Michael D. Coleman - Glen Mills PA, US
Xiaolei Hu - Aurora IL, US

Ball Horticultural Company - West Chicago IL

H04N 9/47
G06K 9/00

348135, 382100

This disclosure relates to a method and system that models a seed structure and uses a spectral analysis to identify which morphological seed structures are existent in the seed/seedling. Additionally, this disclosure relates to a method and system that applies multi-spectral analysis using predetermined models of a seed/seedling to identify which morphological structures are existent in the seed/seedling. The information about the existence or non-existence of structures of the seed/seedling is used to classify the seed as having a specific characteristic, for later commercial use or sale. The seed market determines which specific characteristic the method will use to classify the seed/seedling. The individual seed classification may help determine associated seed lot germination values.

20070275911, Nov 29, 2007

Sep 7, 2004

10/570471

Tad Koch - Boulder CO, US
Michael Coleman - Louisville CO, US
Peter Cogan - Boulder CO, US
Patrick Burke - Seattle WA, US
Glen Post - Spokane WA, US
David Burkhart - Spokane WA, US
Andrew McKenzie - Belmont MA, US
Katrina Jackson - Boulder CO, US
Brian Kalet - Boulder CO, US

A61K 38/14
A61K 31/497
C07D 401/02
C07H 15/252
A61K 31/704

514034000, 514187000, 514253060, 514312000, 514053000, 536055000, 536006400, 544363000, 546010000, 546156000, 514008000

The invention provides a prodrug platform technology for improving the therapeutic value of a variety of parent drug compounds by altering and improving drug characteristics such as aqueous solubility, hydrolytic stability, therapeutic index, toxicity profile, pharmacolcinetics and selectivity while allowing the potential for synthetic elaboration. The prodrug platform is particularly well suited for targeting therapeutic drugs, including anti-tumor drugs and antibiotics, to specific receptors on target cells (e.g., cancer cells and bacteria). The platform is a technology for providing an improved, preactivated form of a therapeutic drug, and for optionally targeting such drug to target cells or biological molecules. The invention is broadly applicable to many different therapeutic drugs, as well as to a variety of diseases and conditions, including a variety of forms of cancer and bacterial infections.